Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Estudysite

Neither a doctor nor a teaching hospital

Research payments

$12,835,138

1,249 payments

Through program year 2025, Estudysite is reported as receiving $12,835,138 in research payments, across 1,249 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,194 1
2024 Research $75,946 3
2023 Research $31,873 180
2022 Research $4,281,505 476
2021 Research $3,806,254 231
2020 Research $3,489,227 193
2019 Research $1,148,140 165

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $6,236,014 390 payments
  2. Roche Products Limited $1,334,330 32 payments
  3. Alnylam Pharmaceuticals Inc. $1,196,230 117 payments
  4. Genentech, Inc. $1,109,686 44 payments
  5. Hoffmann-La Roche Limited $860,214 25 payments
  6. Novartis Pharmaceuticals Corporation $440,792 10 payments
  7. Intercept Pharmaceuticals, Inc. $392,039 117 payments
  8. AbbVie, Inc. $351,469 25 payments
  9. GlaxoSmithKline, LLC. $179,128 14 payments
  10. Paratek Pharmaceuticals, Inc. $160,059 30 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $5,322,243 341 payments
  2. Covacta Actemra Covid 19 Pneumonia Study $1,334,330 32 payments
  3. Phii Il22fc Anti St2 in Severe Covid 19 Pneumonia $1,063,243 31 payments
  4. Safety Efficacy of A Combination of Remdesivir Tocilizumab in Severe Covid 19 Pneumonia $860,214 25 payments
  5. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $707,918 20 payments
  6. A Phase 2, Randomized, Placebo-Controlled, Participant and Investigator Blinded, Multi-Center Study to Assess Efficacy and Safety of Mas825 for the Treatment of Sars-Cov-2 Infected Patients With Covid-19 Pneumonia and Impaired Respiratory Function $417,776 4 payments
  7. The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) $268,389 21 payments
  8. The Study of an Investigational Drug, Patisiran ALN-TTR02, for the Treatment of Transthyretin TTR-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 Patisiran $245,774 16 payments
  9. A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ABBV-181 in HIV-1 Infected Adults $220,086 11 payments
  10. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $183,353 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record